多西环素暴露后预防与淋球菌耐药:ANRS 174 DOXYVAC 子研究
该子研究纳入男男性行为者(MSM)并正在接受HIV暴露前预防者,随机分为多西环素暴露后预防(DoxyPEP)组(n=362)和无暴露后预防组(n=183),基线与每3个月检测淋球菌并行药敏及分子耐药分析。DoxyPEP组高水平四环素耐药(tetM介导)比例显著升高(35.5% vs 12.5%,P=.043),且对头孢克肟敏感性下降(mosaic penA34.007等位基因)更常见(32.3% vs 10.0%,P=.033);所有分离株对头孢曲松和头孢克肟敏感,头孢曲松、氟喹诺酮类和阿奇霉素MIC分布两组相似。
要点
- DoxyPEP与淋球菌高水平四环素耐药(tetM介导)比例显著升高相关。
- DoxyPEP组携带mosaic penA34.007等位基因、头孢克肟敏感性下降的分离株更常见。
- 使用DoxyPEP策略时应密切监测淋球菌抗菌药物耐药性。
核心结论
- DoxyPEP使用与淋球菌高水平四环素耐药及头孢克肟敏感性下降显著增加相关。
研究设计与样本
- ANRS 174 DOXYVAC试验子研究,MSM并接受HIV暴露前预防者随机分为DoxyPEP组(n=362)或无PEP组(n=183)。
- 基线与每3个月通过培养和核酸扩增检测淋球菌,采用Etest测定MIC并按EUCAST判读。
- 对淋球菌分离株及NAAT阳性样本进行全基因组测序和/或PCR测序,比较用Fisher精确检验。
主要发现
- 共测定78株淋球菌分离株MIC,并分析233份NAAT-only淋球菌阳性样本的耐药分子决定因素。
- 所有淋球菌分离株均对四环素耐药;DoxyPEP组高水平四环素耐药(tetM介导)比例显著高于无PEP组(35.5% vs 12.5%,P=.043)。
- 头孢曲松、氟喹诺酮类和阿奇霉素MIC在DoxyPEP组与无PEP组分布相似。
- 所有分离株对头孢曲松和头孢克肟敏感,但DoxyPEP组头孢克肟敏感性下降(mosaic penA34.007等位基因)更常见(32.3% vs 10.0%,P=.033)。
关键数值与推荐
- 高水平四环素耐药(tetM介导):DoxyPEP组35.5% vs 无PEP组12.5%,P=.043。
- 头孢克肟敏感性下降(mosaic penA34.007等位基因):DoxyPEP组32.3% vs 无PEP组10.0%,P=.033。
- 所有淋球菌分离株对头孢曲松和头孢克肟敏感;头孢曲松、氟喹诺酮类和阿奇霉素MIC两组分布相似。
临床怎么用
- 采用DoxyPEP预防细菌性性传播感染时,应密切监测淋球菌对四环素及头孢克肟的耐药性变化。
- 对使用DoxyPEP者出现的淋球菌感染,需关注高水平四环素耐药和头孢克肟敏感性下降的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prevention of bacterial sexually transmitted infections prevention by doxycycline postexposure prophylaxis (DoxyPEP) in men who have sex with men has raised concerns about antimicrobial resistance (AMR). We studied the impact of DoxyPEP on Neisseria gonorrhoeae (gonococcus [GC]) AMR in the ANRS 174 DOXYVAC trial. METHODS: Men who have sex with men and were on human immunodeficiency virus preexposure prophylaxis randomized to DoxyPEP (n = 362) or no-postexposure prophylaxis (PEP) (n = 183) arms were tested for GC at baseline and every 3 months thereafter, by culture and nucleic acid amplification test (NAAT). Minimum inhibitory concentrations (MICs) were determined with Etest (bioMérieux) and interpreted according to European Committee on Antimicrobial Susceptibility Testing guidelines. We performed whole-genome sequencing and/or polymerase chain reaction sequencing on GC isolates and NAAT-positive samples, using Fisher exact tests for comparisons. RESULTS: From January 2021 to February 2023, MICs were determined for 78 GC isolates, and 233 NAAT-only GC-positive samples were analyzed to identify the molecular determinants of resistance. All GC isolates were resistant to tetracycline with a significant increase in the rate of high-level tetracycline resistance mediated by the tetM gene in the DoxyPEP arm compared with the no-PEP arm (35.5 vs 12.5%, respectively; P = .043). The MICs of ceftriaxone, fluoroquinolones, and azithromycin were similarly distributed in the DoxyPEP and no-PEP arms. All GC isolates were susceptible to ceftriaxone and cefixime, but isolates with decreased susceptibility to cefixime linked to the mosaic penA34.007 allele were more frequent in the DoxyPEP arm than the no-PEP arm (32.3% vs 10.0%, respectively; P = .033). CONCLUSIONS: DoxyPEP use was associated with a significant increase in high-level tetracycline resistance and decreased susceptibility to cefixime in GC. AMR should therefore be closely monitored when using this strategy.
引用
- Berçot B, Assoumou L, Caméléna F, et al. Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial. Clin Infect Dis. 2026. PMID: 41208026. doi:10.1093/cid/ciaf591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。